Kynurenic acid

Kynurenate, Quinurenic acid, Transtorine
An Antagonist of Ionotropic Glutamate Receptors and α7 nAChR
Cat #: K-110
Alternative Name Kynurenate, Quinurenic acid, Transtorine
  • Lyophilized Powder
  • Bioassay Tested
  • Source Synthetic
    MW: 189.2
    Purity: >98%
    Form Lyophilized powder.
    Effective concentration 1 µM - 2 mM.
    Chemical name 4-oxo-1H-quinoline-2-carboxylic acid.
    Molecular formula C10H7NO3.
    CAS No.: 492-27-3.
    Activity Kynurenic acid antagonizes ionotropic glutamate receptors with IC50 values of 33 µM (GluK2), 130 µM (GluK1). 100 µM - 3mM antagonizes NMDA response in rat spinal cord.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility Up to 50mM in DMSO or in equimolar NaOH. Mild warming (37°C-42°C) and agitation may be required.
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
      • Alomone Labs Kynurenic acid inhibits NMDA (NR1+NR2A) channels expressed in Xenopus oocytes. 
        A. Time course of NMDA currents elicited by stimulation with 100 µM glutamate and 100 µM glycine, every 50 sec, while membrane potential was held at -80 mV. 100 and 250 µM Kynurenic acid (#K-110), applied for 3 min each, reversibly inhibited current amplitude. B. Superimposed current traces taken from the experiment described in A.
      • Kynurenic acid (KYNA) is a neuroactive metabolite of the kynurenine pathway of tryptophan degradation. It is a competitive and broad spectrum antagonist of glutamate receptors. Additionally, KYNA antagonizes α7 nicotinic acetylcholine receptor and G-protein coupled GPR35 receptor. KYNA is widely used as a pharmacological tool to experimentally eliminate activation of all these receptors in vivo or in vitro1-3.

        Kynurenine can influence brain function and its levels in the human brain are significantly higher compared to those in other species. Its levels in the brain are normally determined by local neosynthesis from its bioprecursor kynurenine pathway metabolite, since KYNA is not actively transported through the blood-brain barrier.

        KYNA serves as a substrate for the probenecid-sensitive organic anion transporters OAT1 and OAT3. These proteins are present in brain capillary endothelial cells, thus it is likely that these proteins play an important role in the elimination of KYNA from the brain’s extracellular compartment2.

        KYNA has antioxidant properties and has the ability to eliminate hydroxyl, superoxide anion and other free radicals3.

        It has been documented that in animal models KYNA may have a positive influence on the number of pathologies in the gastrointestinal tract such as ulcers, colon obstruction and colitis1.

    Target iGluR, α7 nAChR
    Last update: 03/06/2019

    Kynurenic acid (#K-110) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use